Research programme: anticancer antibodies - Arana Therapeutics/NIH
Alternative Names: ART160; EGX-160Latest Information Update: 09 Mar 2011
At a glance
- Originator EvoGenix; National Institutes of Health (USA)
- Developer Arana Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 16 Mar 2009 Research is ongoing in USA
- 07 Nov 2006 Early research in Cancer in USA (unspecified route)